As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML and from the LMICs.

Read Professor Hughes' CML publications of the month: June 2024

Clinical CML papers 

• Asciminib in newly diagnosed chronic myeloid leukemia
  Hochhaus A et al. N Eng J Med, May 2024 (epub ahead of print)
• Is there really an accelerated phase of chronic myeloid leukemia? Review
  Gale RP et al. Leukemia, June 2024 (epub ahead of print) – open access publication
• Clinical outcomes of chronic myeloid leukemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
  Chee L et al. Intern Med J, June 2024 (epub ahead of print) – open access publication
• Point-of-care BCR::AB1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients
  Sala-Torra O et al. Leukemia, June 2024 (epub ahead of print) – open access publication
• Comparison of the efficacy among nilotinib, dasatinib, flumatinib and imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients: A real-world multi-center retrospective study
  Zhang X et al Clin Lymphoma Myeloma Leuk, June 2024
• Variant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia
  Jacobs K et al. Int J Lab Hematol, June 2025 (epub ahead of print)
• Treatment-free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): From feasibility to safety
  Laganà A et al. Expert Opin Drug Saf, Jue 2024 (epub ahead of print)
• Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia
  Gover-Proactor A et al. Br J Haematol, June 2024 (epub ahead of print) – open access publication
• Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia
  Yang Y et al. Haematologica, June 2024 (epub ahead of print) – open access publication
• Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials
  Shin DY et al. Leuk Res, June 2024 (epub ahead of print)
• CML in the very elderly: The impact of comorbidities and TKI selection in a real-life multicentre study
  Rozental A et al. Ann Hematol, June 2024 (epub ahead of print)

Scientific CML papers

• Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia
  Khalaf A et al. Sci Transl Med, June 2024
• HIF-2alpha inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment
  Wang J et al. Cancer Lett, June 2024 (epub ahead of print)
• Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia
  Minhajuddin M et al. Haematologica, June 2024 (epub ahead of print)
• RNA binding protein Lin28B promotes chronic myeloid leukemia blast crisis by transcriptionally upregulating miR-181d
  Zhou M et al. Mol Cancer Res, June 2024 (epub ahead of print)
• The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to ascinimib
  Leske IB & Hantschel O. Leukemia, June 2024 (epub ahead of print) – open access publication
• Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells
  Chatain N et al. Leukemia, June 2024 – open access publication

Pediatric CML papers

• Childhood chronic myeloid leukemia treatment (PDQ): Health Professional Version - Review
  PDQ Pediatric Treatment Editorial Board June 2024
  In: PDQ Cancer Information Summaries (Internet) Bethesada (MD) National Cancer Institute (US); 2002-.

LMIC CML papers

• Prognostic role of human leukocyte antigen alleles and cytokine single-nucleotide polymorphisms in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor drugs
  Birru SK et al. Genes(Basel), June 2024 – open access publication
  
  

Read Professor Hughes' summaries of key CML publications

This series of paper summaries is an extension of Professor Tim Hughes' 'CML publications of the month' news service.
These summaries, selected and curated by Professor Hughes, will be compiled and provided every three months, offering a comprehensive overview of key CML papers. This approach ensures that clinicians, researchers, and healthcare professionals stay up-to-date with important pivotal studies and emerging trends in CML research.

CML paper highlight #1  - July 2024: Asciminib in newly diagnosed CML (Hochhaus A et al. NEJM, May 2024)
Link to full paper (ClinicalTrials.gov no. NCT04971226)

Read more